A multicenter real-world analysis of risk factors, therapeutics, and outcomes of patients with metastatic basal cell carcinoma.

Autor: Groover M; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Gupta N; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Granger E; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Forrester VJ; Department of Dermatology, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio., Anstadt EJ; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Su W; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Heusinkveld L; Department of Dermatology, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio., Chen A; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Lukens JN; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Silk AW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Vidimos AT; Department of Dermatology, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio., Schoenfeld JD; Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Koyfman SA; Department of Radiation Oncology, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio., Ruiz ES; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: esruiz@bwh.harvard.edu.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Mar; Vol. 90 (3), pp. 545-551. Date of Electronic Publication: 2023 Nov 08.
DOI: 10.1016/j.jaad.2023.10.060
Abstrakt: Background: Metastatic basal cell carcinoma (mBCC) is rare and there are limited data regarding patient and tumor risk factors, optimal treatments, and disease prognosis.
Objective: To assess patient and tumor characteristics, therapeutics, and outcomes of mBCC stratified by location of metastasis.
Methods: Retrospective cohort study of 53 patients with mBCC treated at 4 large academic centers in Boston, Massachusetts; Philadelphia, Pennsylvania; and Cleveland, Ohio between January 1, 2005 and December 31, 2021.
Results: A total of 53 patients with mBCC were identified across 4 centers, 22 (42%) of whom had mBCC with spread limited to lymph nodes and 31 (58%) patients with distant organ spread (with or without lymph node involvement). Overall, half (n = 11) of patients with nodal metastasis achieved complete remission of disease, compared with just 1 (3%) patient with distant metastasis. The 5-year survival for nodal and distant metastatic patients was 89.3% and 61.0%, respectively.
Limitations: Small sample size due to disease rarity.
Conclusions and Relevance: Patients with nodal disease are more likely to have disease remission whereas patients with distant metastasis are more likely to have persistent disease and die from their disease. However, 5-year survival rates exceed 50%, even for stage IV disease.
Competing Interests: Conflicts of interest Dr Ruiz has received research support from Regeneron and Pellepharm, and has consulted for Regeneron, Checkpoint Therapeutics, and Feldan Therapeutics. Dr Silk has received research support from Biohaven Pharmaceuticals, Replimune, Morphogenesis, Shattuck Laboratories, Regeneron, and Merck, is a member of the Regeneron Ad Board as of July 2023, and is on the Board of Directors of the Society for Immunotherapy of Cancer. Dr Schoenfeld has received research support from Merck, BMS, Regeneron, Debiopharm, and EMD Serono, has consulting, scientific advisory board, and travel fee relationships with Castle Biosciences, Genentech, Immunitas, Debiopharm, BMS, Tilos, ACI Clinical, Astellas, Stimit, Merck KGA, SIRPant, and EMD Serono, has received expert witness fees from Pearson Doyle Mohre & Pastis, is a member of the Data Safety Monitoring or Advisory Board at ACI Clinical, EMD Serono, and Merck KGA, has stock options in Immunitas, and has equity in Doximity. Dr Koyfman has received research support from Merck, BMS, Castle Biosciences, and Regeneron, has consulted for Merck, Regeneron, and Galera, writes for Up To Date, and is a member of the advisory board for Alpha Part. The other authors have no conflicts of interest to declare.
(Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: